Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PLC Systems -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (1179)	3/28/2000 5:59:00 PM
From: Rob C.	Read Replies (1) \| Respond to of 1202

Tuck, This will pop someday! With Institutional Investors FRANKLIN, Mass., March 28 /PRNewswire/ -- PLC Systems Inc. (Amex: PLC), the leader in carbon dioxide (CO2) transmyocardial revascularization (TMR), today announced it has raised gross proceeds of $5,366,000 through the sale of 2,683,000 shares of its common stock to two institutional investors. "Over the past month interest in PLC has increased and we were able to avail ourselves of this opportunity to quickly and efficiently raise capital utilizing our 'shelf' registration," said James Thomasch, Chief Financial Officer of PLC. "The proceeds from this financing will be utilized to increase PLC's sales staff and marketing initiatives, as well as for other working capital purposes," stated PLC Systems' President and CEO Mark Tauscher. "The additional sales coverage will assist us in promoting and communicating the key benefits of TMR with The Heart Laser System. We also believe the additional financial resources will enable the Company to continue fostering new technology development." Working with leading researchers and premier heart surgery centers around the world, PLC developed the world's first FDA-approved TMR device, a high- powered laser known as The Heart Laser System. Designed to perform TMR in the safest manner possible, The Heart Laser System was approved by the U.S. Food and Drug Administration in August of 1998 for treatment of the estimated 80,000 domestic patients each year who suffer from severe coronary artery disease but cannot be treated with conventional coronary revascularization techniques such as bypass surgery or angioplasty. For more information on PLC and its products, please visit the Company's Web site at www.bloodlinelaser.com or www.plcmed.com. Note: Certain of the above statements are forward-looking statements that involve risks and uncertainties. Actual results could differ materially from those indicated by such forward-looking statements as a result ofa variety of factors, including operational changes, competitive developments, regulatory approval requirements, the ability to convince health care professionals and third party payers of the medical and economic benefits of The Heart Laser System, no assurance that all payers will reimburse health care providers who perform TMR procedures or that reimbursement, if provided, will be adequate, and risk factors described in the Company's current report on Form 8-K filed with the SEC on March 27, 2000. SOURCE PLC Systems Inc. -0- 03/28/2000 /CONTACT: John Jordan, Manager of Investor Relations of PLC Systems Inc., 508-541-8800, ext. 145/ /Web site: plcmed.com (PLC) CO: PLC Systems Inc. ST: Massachusetts IN: MTC SU: LR -- NETU048 -- 3199 03/28/2000 16:05 EST prnewswire.com